{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:57:04Z","timestamp":1758632224762,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12328-019-00972-0","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T15:05:34Z","timestamp":1554217534000},"page":"466-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-2736","authenticated-orcid":false,"given":"Kai","family":"Adachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Okuwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasaburo","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"972_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","volume":"16","author":"S Miyasaka","year":"2009","unstructured":"Miyasaka S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1\u20137.","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"972_CR3","first-page":"e415","volume":"17","author":"YS Rho","year":"2015","unstructured":"Rho YS, Barrera I, Metrakos P, et al. Complete resolution of metastatic gallbladder cancer after standard gemcitabine-cisplatin combination therapy. Cureus. 2015;17:e415.","journal-title":"Cureus"},{"issue":"Suppl 3","key":"972_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-015-4768-9","volume":"22","author":"A Kato","year":"2015","unstructured":"Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093\u20139.","journal-title":"Ann Surg Oncol"},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-009-1055-0","volume":"65","author":"A Sharma","year":"2010","unstructured":"Sharma A, Mohanti B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2010;65:497\u2013502.","journal-title":"Cancer Chemother Pharmacol"},{"key":"972_CR6","first-page":"106","volume":"5","author":"D Moussata","year":"2012","unstructured":"Moussata D, Bessayah A, Chauvenet M, et al. A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Cancer Res. 2012;5:106\u20138.","journal-title":"Cancer Res"},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5009\/gnl.2013.7.3.371","volume":"7","author":"JH Lim","year":"2013","unstructured":"Lim JH, Ryu JK, Choi YJ, et al. A case of common bile duct cancer that completely responded to combination chemotherapy of gemcitabine and TS-1. Gut Liver. 2013;7:371\u20136.","journal-title":"Gut Liver"},{"key":"972_CR8","first-page":"1771","volume":"37","author":"R Yoshida","year":"2010","unstructured":"Yoshida R, Matsuda T, Watanabe T, et al. A case of gallbladder cancer which completely responded to gemcitabine. Gan To Kagaku Ryoho. 2010;37:1771\u20133.","journal-title":"Gan To Kagaku Ryoho"},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","volume":"127","author":"DB Evans","year":"1992","unstructured":"Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreatico-duodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335\u20139.","journal-title":"Arch Surg"},{"key":"972_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer. A comparative multicenter study in Japan. Br J Cancer. 2010;103:469\u201374.","journal-title":"Br J Cancer"},{"key":"972_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211\u20136.","journal-title":"Cancer Sci"},{"key":"972_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/jjco\/hyv213","volume":"46","author":"J Mizusawa","year":"2016","unstructured":"Mizusawa J, Morizane C, Okusaka T, et al. Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46:385\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2012;13:181\u20138.","journal-title":"Lancet Oncol"},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, et al. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Hepatology. 2014;59:1427\u201334.","journal-title":"Hepatology"},{"key":"972_CR15","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1038\/ncomms7087","volume":"6","author":"D Sia","year":"2015","unstructured":"Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.","journal-title":"Nat Commun"},{"key":"972_CR16","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427\u201334.","journal-title":"Hepatology"},{"key":"972_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","volume":"3","author":"YM Wu","year":"2013","unstructured":"Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636\u201347.","journal-title":"Cancer Discov"},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/cas.12501","volume":"105","author":"T Okusaka","year":"2014","unstructured":"Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321\u20136.","journal-title":"Cancer Sci"},{"key":"972_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"972_CR21","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Hoff Von","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29:4548\u201354.","journal-title":"J Clin Oncol"},{"key":"972_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, et al. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595\u2013603.","journal-title":"Cancer Chemother Pharmacol"},{"key":"972_CR23","doi-asserted-by":"publisher","first-page":"e78977","DOI":"10.1371\/journal.pone.0078977","volume":"8","author":"JK Park","year":"2013","unstructured":"Park JK, Paik WH, Ryu JK, et al. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977.","journal-title":"PLoS One"},{"key":"972_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/COC.0b013e3181a76a0b","volume":"33","author":"M Choi","year":"2010","unstructured":"Choi M, Heibrun LK, Venkatramanamoorthy R, et al. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemoradiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2010;33:257\u201361.","journal-title":"Am J Clin Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-019-00972-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T02:43:55Z","timestamp":1663209835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-019-00972-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-00972-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"22 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors state that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}